{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:50:20Z","timestamp":1789498220806,"version":"build-2803163510"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Rituximab is a CD20-directed cytolytic antibody used for non-Hodgkin lymphoma, chronic lymphocytic leukaemia and RA, and off label for JIA, multiple sclerosis and lupus. Owing to concerns about infant B cell depletion, the manufacturer recommends avoidance of rituximab throughout pregnancy and for 12\u2009months before conception. The aim of this study was to add to the limited data on pregnancy outcomes in women with exposure to rituximab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were obtained from MotherToBaby Pregnancy Studies. Participants were enrolled prospectively into this observational study between 2007 and 2019. Pregnancy exposure and outcome data were collected from medical records, telephone interviews and dysmorphology examinations. The outcomes examined included spontaneous abortion, stillbirth, premature delivery, pregnancy complications, major and minor anomalies, small for gestational age, neonatal complications and serious infections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We classified 19 women with exposure to rituximab into three groups. Group\u00a0A included three women who received rituximab during pregnancy. Group\u00a0B included three women who received their last infusion before conception but had assumed pregnancy exposure owing to the long half-life of the drug. Group\u00a0C included 13 women who used rituximab in the 2\u2009years before pregnancy, with the last infusion given no sooner than five half-lives before conception. Three children had a major structural defect. Preterm delivery occurred in two pregnancies, and two infants were small for gestational age on birth weight. No cases of B\u00a0cell depletion were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>No pattern of major structural anomalies or other adverse outcomes was reported in this case series.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkaa074","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T18:05:05Z","timestamp":1609783505000},"source":"Crossref","is-referenced-by-count":44,"title":["Pregnancy outcomes following maternal treatment with rituximab prior to or during pregnancy: a case series"],"prefix":"10.1093","volume":"5","author":[{"given":"Kirstie","family":"Perrotta","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of California, San Diego (UCSD), La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1814-8017","authenticated-orcid":false,"given":"Elizabeth","family":"Kiernan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Diego (UCSD), La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Bandoli","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Diego (UCSD), La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Manaster","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Diego (UCSD), La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chambers","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Diego (UCSD), La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"2021012419395281900_rkaa074-B1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0091270007305297","article-title":"Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response","volume":"47","author":"Breedveld","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"2021012419395281900_rkaa074-B2","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"key":"2021012419395281900_rkaa074-B3","first-page":"iii28","article-title":"Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs","volume":"47(suppl_3","author":"\u00d8stensen","year":"2008","journal-title":"Rheumatology"},{"key":"2021012419395281900_rkaa074-B4","author":"Rituxan website","year":"2019"},{"key":"2021012419395281900_rkaa074-B5","doi-asserted-by":"crossref","first-page":"e20154256","DOI":"10.1542\/peds.2015-4256","article-title":"Updated clinical guidelines for diagnosing fetal alcohol spectrum disorders","volume":"138","author":"Hoyme","year":"2016","journal-title":"Pediatrics"},{"key":"2021012419395281900_rkaa074-B6","author":"Division of Reproductive Health","year":"2020"},{"key":"2021012419395281900_rkaa074-B7","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/acr.23730","article-title":"Factors associated with preterm delivery among women with rheumatoid arthritis and women with juvenile idiopathic arthritis","volume":"71","author":"Smith","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2021012419395281900_rkaa074-B8","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1016\/j.vaccine.2017.01.040","article-title":"Small for gestational age: case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data","volume":"35","author":"Schlaudecker","year":"2017","journal-title":"Vaccine"},{"key":"2021012419395281900_rkaa074-B9","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD","volume":"5","author":"Das","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2021012419395281900_rkaa074-B10","year":"2020"},{"key":"2021012419395281900_rkaa074-B11","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.V84.6.1851.1851","article-title":"Fetal thrombocytopenia: a retrospective survey of 5,194 fetal blood samplings","volume":"84","author":"Hohlfeld","year":"1994","journal-title":"Blood"},{"key":"2021012419395281900_rkaa074-B12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM198807213190304","article-title":"Incidentally detected thrombocytopenia in healthy mothers and their infants","volume":"319","author":"Burrows","year":"1988","journal-title":"New Engl J Med"},{"key":"2021012419395281900_rkaa074-B13","first-page":"441","article-title":"Thrombocytopenia in term infants: a population-based study","volume":"95","author":"Sainio","year":"2000","journal-title":"Obstetr Gynecol"},{"key":"2021012419395281900_rkaa074-B14","doi-asserted-by":"crossref","first-page":"e734","DOI":"10.1212\/NXI.0000000000000734","article-title":"Rituximab, MS, and pregnancy","volume":"7","author":"Smith","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2021012419395281900_rkaa074-B15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.reprotox.2019.05.015","article-title":"#3 Pregancy and infant outcomes after maternal exposure to rituximab","volume":"88","author":"Zagorodnikova","year":"2019","journal-title":"Reprod Toxicol"},{"key":"2021012419395281900_rkaa074-B16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/tera.1420130109","article-title":"Some aspects of the epidemiology of human minor birth defects and morphological variants in a completely ascertained newborn population (Madison study)","volume":"13","author":"Hook","year":"1976","journal-title":"Teratology"},{"key":"2021012419395281900_rkaa074-B17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.clp.2015.02.002","article-title":"Evaluation and diagnosis of the dysmorphic infant","volume":"42","author":"Jones","year":"2015","journal-title":"Clin Perinatol"},{"key":"2021012419395281900_rkaa074-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00019605-200101000-00001","article-title":"Humoral immunodeficiency with facial dysmorphology and limb anomalies: a new syndrome","volume":"10","author":"Hoffman","year":"2001","journal-title":"Clin Dysmorphol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkaa074\/35387363\/rkaa074.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/1\/rkaa074\/36091094\/rkaa074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/1\/rkaa074\/36091094\/rkaa074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:40:03Z","timestamp":1611535203000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkaa074\/6062415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,22]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkaa074","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021]]},"published":{"date-parts":[[2021]]},"article-number":"rkaa074"}}